Solid Biosciences (SLDB) Assets Average (2018 - 2026)

Solid Biosciences has disclosed Assets Average across 9 years of filings, most recently posting $327.7 million for Q1 2026.

• Assets Average for Q1 2026 came in at $327.7 million, up 23.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $327.7 million (up 23.07% YoY), and the FY2025 annual result was $210.6 million, up 19.12% from the prior year.
• Assets Average came in at $327.7 million for Q1 2026 at Solid Biosciences, up from $253.2 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $327.7 million in Q1 2026 to a low of $174.8 million in Q4 2023.
• The 5-year median for Assets Average is $221.4 million (2024), against an average of $236.0 million.
• Across the five-year window, Assets Average dropped 24.51% in 2022 and jumped 35.97% in 2025, its largest moves.
• Solid Biosciences' Assets Average stood at $222.4 million in 2022, then slipped by 21.37% to $174.8 million in 2023, then rose by 14.53% to $200.2 million in 2024, then gained by 26.46% to $253.2 million in 2025, then increased by 29.42% to $327.7 million in 2026.
• The last three Assets Average figures came in at $327.7 million (Q1 2026), $253.2 million (Q4 2025), and $291.1 million (Q3 2025), per Business Quant data.